Last reviewed · How we verify
Travelan
Travelan is a Biologic drug developed by Immuron Ltd.. It is currently in Phase 2 development. Also known as: IMM-124E.
Travelan is a dietary supplement used to prevent travelers' diarrhea, and it has also been studied for its potential effects on other conditions such as COVID-19 and asymptomatic chronic HCV carriers. The exact mechanism of Travelan is not specified, but it is available in various forms, including Travelan and bovine colostrum powder.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Travelan |
|---|---|
| Also known as | IMM-124E |
| Sponsor | Immuron Ltd. |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model (PHASE2)
- Trial to Evaluate Dietary Supplements to Maintain Gut Health During Travel (NA)
- Using Travelan to Boost Immune Response in Vitro to COVID-19 (PHASE1, PHASE2)
- Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Travelan CI brief — competitive landscape report
- Travelan updates RSS · CI watch RSS
- Immuron Ltd. portfolio CI
Frequently asked questions about Travelan
What is Travelan?
Who makes Travelan?
Is Travelan also known as anything else?
What development phase is Travelan in?
Related
- Manufacturer: Immuron Ltd. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: IMM-124E
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing